U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C33H34N4O6
Molecular Weight 582.6475
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of AZELNIDIPINE

SMILES

CC(C)OC(=O)C1=C(C)NC(=C(C1c2cccc(c2)N(=O)=O)C(=O)OC3CN(C3)C(c4ccccc4)c5ccccc5)N

InChI

InChIKey=ZKFQEACEUNWPMT-UHFFFAOYSA-N
InChI=1S/C33H34N4O6/c1-20(2)42-32(38)27-21(3)35-31(34)29(28(27)24-15-10-16-25(17-24)37(40)41)33(39)43-26-18-36(19-26)30(22-11-6-4-7-12-22)23-13-8-5-9-14-23/h4-17,20,26,28,30,35H,18-19,34H2,1-3H3

HIDE SMILES / InChI

Molecular Formula C33H34N4O6
Molecular Weight 582.6475
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description
Curator's Comment:: http://www.ube-ind.co.jp/english/news/2003/2003_03.htm

Azelnidipine (INN; marketed under the brand name CalBlock) is a dihydropyridine calcium channel blocker. It is sold in Japan by Daiichi-Sankyo pharmaceuticals, Inc. Azelnidipine is a new dihydropyridine calcium channel antagonist with selectivity for both L-type and T-type Ca channels. It has recently been approved in Japan for the treatment of patients with hypertension. Results from clinical trials showed that long-term treatment with azelnidipine effectively controls blood pressure (BP) in a cohort of 95 patients with mild-to-moderate hypertension. The antihypertensive efficacy of azelnidipine in patients with mild-to-moderate hypertension was shown to be similar to that of amlodipine or nitrendipine in a randomised double-blind study. Azelnidipine and amlodipine controlled 24-hour BP to a similar extent. Azelnidipine is generally well tolerated. Vasodilator adverse events such as headache and hot facial flushes account for most of the adverse events. Its use is not associated with reflex tachycardia.

CNS Activity

Curator's Comment:: Although no study is available to demonstrate whether azelnidipine crosses the blood-brain barrier, the inhibitory action of azelnidipine may be explained by its action on the central nervous system

Approval Year

TargetsConditions

Conditions

PubMed

PubMed

TitleDatePubMed
Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker.
1989 Sep
Chronotropic effects of azelnidipine, a slow- and long-acting dihydropyridine-type calcium channel blocker, in anesthetized dogs: a comparison with amlodipine.
2009 Apr
Patents

Sample Use Guides

The normal dose for an adult is 8-16 mg of azelnidipine once daily, taken orally after breakfast. The maximum dosage is 16 mg/day. The initial dosage is to be 8 mg/day or less, to be adjusted as symptoms are monitored, up to 16 mg daily.
Route of Administration: Oral
azelnidipine inhibited rat aortic smooth muscle cell (RASMC) death in a concentration-dependent manner (10-100 nM) as well as inhibited JNK and p38 activation by mechanical stretch
Substance Class Chemical
Created
by admin
on Fri Jun 25 22:46:47 UTC 2021
Edited
by admin
on Fri Jun 25 22:46:47 UTC 2021
Record UNII
PV23P19YUG
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
AZELNIDIPINE
INN   JAN   MART.   MI   WHO-DD  
INN  
Official Name English
CALBLOCK
Brand Name English
AZELNIDIPINE [MI]
Common Name English
AZELNIDIPINE [INN]
Common Name English
AZELNIDIPINE [MART.]
Common Name English
AZELNIDIPINE [WHO-DD]
Common Name English
AZELNIDIPINE [JAN]
Common Name English
3-(1-(DIPHENYLMETHYL)-3-AZETIDINYL) 5-ISOPROPYL (+/-)-2-AMINO-1,4-DIHYDRO-6-METHYL-4-(M-NITROPHENYL)-3,5-PYRIDINEDICARBOXYLATE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C333
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
Code System Code Type Description
DRUG CENTRAL
272
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
DRUG BANK
DB09230
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
WIKIPEDIA
AZELNIDIPINE
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
NCI_THESAURUS
C73023
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
FDA UNII
PV23P19YUG
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
INN
7109
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
PUBCHEM
65948
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
MERCK INDEX
M2170
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY Merck Index
ChEMBL
CHEMBL1275868
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
MESH
C061679
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
CAS
123524-52-7
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
EVMPD
SUB05650MIG
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
EPA CompTox
123524-52-7
Created by admin on Fri Jun 25 22:46:47 UTC 2021 , Edited by admin on Fri Jun 25 22:46:47 UTC 2021
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY